Q4 2025 Management View CEO Dikla Akselbrad described 2025 as “a pivotal year for PolyPid,” highlighting the completion of ...
KalVista Pharmaceuticals, Inc. is rated a Strong Buy due to EKTERLY's global launch and robust initial sales momentum. Read ...
Exelixis, Inc. (NASDAQ:EXEL) Q4 2025 Earnings Call Transcript February 10, 2026 Exelixis, Inc. beats earnings expectations. Reported EPS is $0.94, expectations were $0.77. Operator: Good day, ladies ...
12h
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results
The Company is in AdvancedStagesof Commercial U.S. Partnership Discussions for D-PLEX₁₀₀Positive FDA Pre-NDA Feedback Supports Rolling NDA ...
Spero Therapeutics’ oral antibiotic tebipenem shows Phase 3 success and supports GSK’s NDA resubmission. Click here to read ...
With an off day in between performing at Climate Pledge Arena last August, Lady Gaga ran down to Burien to film a commercial ...
The non-disclosure agreements follow a pattern of secrecy within the technology industry, experts said, amid a public outcry ...
When it’s time to finally sell your company or if you’re exploring a potential acquisition target, one of the first documents you will encounter ...
Completion of a two-year R&D programme moves the technology from theoretical design to technical readiness for commercial ...
LINCOLN – The Nebraska Department of Agriculture (NDA) is reminding poultry owners to continue to monitor for and protect their birds against Highly Pathogenic Avian Influenza (HPAI). In late December ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results